The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Cancer stem cells in osteosarcoma
Open accessAbstract
Osteosarcoma is the most common primary bone tumour in children and adolescents and advanced osteosarcoma patients with evidence of metastasis share a poor prognosis. Osteosarcoma frequently gains resistance to standard therapies highlighting the need for improved treatment regimens and identification of novel therapeutic targets. Cancer stem cells (CSC) represent a sub-type of tumour cells attributed to critical steps in cancer including tumour propagation, therapy resistance, recurrence and in some cases metastasis. Recent published work demonstrates evidence of cancer stem cell phenotypes in osteosarcoma with links to drug resistance and tumorigenesis. In this review we will discuss the commonly used isolation techniques for cancer stem cells in osteosarcoma as well as the identified biochemical and molecular markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This seed and soil phenomenon is driven by a microenvironment that modulates osteosarcoma cell behaviour and facilitates proliferation, quiescence, invasion, migration, and drug resistance 15,51,52,53 and contributes to their intrinsic heterogeneity 54,55 .”
From Osteosarcoma (2022) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C., Jamieson, C., Jones, D. L., Visvader, J., Weissman, I. L., & Wahl, G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3126 · Cited by 3,124
Tumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Cancer stem cell definitions and terminology: the devil is in the details
Valent, P., Bonnet, D. A., Maria, R. D., Lapidot, T., Copland, M., Melo, J. V., Chomienne, C., Ishikawa, F., Schuringa, J. J., Stassi, G., et al. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3368 · Cited by 720
Mechanisms of Stem Cell Self-Renewal
He, S., Nakada, D., & Morrison, S. J. (2009) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.042308.113248 · Cited by 644
Stem-Like Cells in Bone Sarcomas: Implications for Tumorigenesis
Gibbs, C. P., Kukekov, V. G., Reith, J. D., Tchigrinova, O., Suslov, O. N., Scott, E. W., Ghivizzani, S. C., Ignatova, T. N., & Steindler, D. A. (2005) · Neoplasia · doi:10.1593/neo.05394 · Cited by 492
Tirino, V., Desiderio, V., Paino, F., ROSA, A. D., Papaccio, F., Noce, M. L., Laino, L., Francesco, F. D., & Papaccio, G. (2012) · The FASEB Journal · doi:10.1096/fj.12-218222 · Cited by 391
Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency
Kovac, M., Blattmann, C., Ribi, S., Smida, J., Mueller, N. S., Engert, F., Castro-Giner, F., Weischenfeldt, J., Kovacova, M., Krieg, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9940 · Cited by 353
Detection and Characterization of CD133+ Cancer Stem Cells in Human Solid Tumours
Tirino, V., Desiderio, V., d’Aquino, R., Francesco, F. D., Pirozzi, G., Galderisi, U., Cavaliere, C., Rosa, A. D., & Papaccio, G. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003469 · Cited by 292
Kim, K., Lee, H. W., Lee, H., Kim, S. C., Seo, Y. J., Chung, W., Eum, H. H., Nam, D., Kim, J., Joo, K. M., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0692-3 · Cited by 269
Cited by
Sorted by citations
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Self-citationCancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 656
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J. H., & Guo, W. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.024 · Cited by 587
Molecular Biology of Osteosarcoma
Czarnecka, A. M., Synoradzki, K. J., Firlej, W., Bartnik, E., Sobczuk, P., Fiedorowicz, M., Grieb, P., & Rutkowski, P. L. (2020) · Cancers · doi:10.3390/cancers12082130 · Cited by 343
Sarcoma treatment in the era of molecular medicine
Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319
Self-citation
Metadata
- Authors
- Brown, H. K., Tellez-Gabriel, M., & Heymann, D.
- Affiliations
- Inserm (FR)
- Corresponding author
- Brown, Hannah K.
- Heymann, Dominique
- ORCID
- Heymann, Dominique
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 386
- Pages
- 189-195
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2551783204
- Cited by
- 303
- References
- 47
- Citations by year
- 2026: 12 · 2025: 23 · 2024: 43 · 2023: 33 · 2022: 41 · 2021: 49 · 2020: 50 · 2019: 34 · 2018: 10 · 2017: 8
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- green
- inserm.hal.science
- Licence
- Locations
- Cancer Letters (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Bone Cancer Research Trust (144681)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- osteosarcoma, cancer stem cells, drug resistance, carcinogenesis, metastasis, cancer stem cell isolation, molecular markers, therapeutic target, pediatric bone tumors
- MeSH terms
- Animals, Antineoplastic Agents, Bone Neoplasms, Cell Separation, Humans, Phenotype, Osteosarcoma, Biomarkers, Tumor, Neoplastic Stem Cells, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
